Study guide
14.3 Male Infertility: Evaluation & Surgical Management
FEBU Part 1 Written European Board of Urology
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Strategy
1.1 FEBU Part 1 Examination Structure & Logistics 1.2 EAU Guidelines Framework & Standard Setting 1.3 Clinical Decision-Making & MCQ Strategy 1.4 Professionalism and Safe Practice
2 Chapter 2: Genitourinary Anatomy & Renal Physiology
2.1 Upper Tract Anatomy & Retroperitoneal Relationships 2.2 Lower Urinary Tract Anatomy & Neuroanatomy 2.3 Renal Physiology, Glomerular Filtration & Acid-Base Balance
3 Chapter 3: Urological Pharmacology & Diagnostic Imaging
3.1 Lower Urinary Tract Pharmacotherapy 3.2 Antimicrobial Stewardship & Perioperative Care 3.3 Diagnostic Modalities: Ultrasound, CT, mpMRI & Nuclear Medicine
4 Chapter 4: Prostate Cancer: Diagnosis & Risk Stratification
4.1 PSA Kinetics, Biomarkers & Risk Assessment 4.2 Multiparametric MRI (PI-RADS) & Biopsy Strategies 4.3 Histopathological Grading (ISUP Gleason) & Staging
5 Chapter 5: Prostate Cancer: Localized & Advanced Management
5.1 Active Surveillance & Watchful Waiting 5.2 Radical Prostatectomy & Radiation Therapy 5.3 Biochemical Recurrence & Salvage Therapies 5.4 Metastatic & Castration-Resistant Prostate Cancer (CRPC)
6 Chapter 6: Bladder Cancer: Non-Muscle Invasive (NMIBC)
6.1 TURBT Technique & Pathological Staging 6.2 EAU Risk Stratification for NMIBC 6.3 Intravesical Chemotherapy & BCG Immunotherapy
7 Chapter 7: Muscle-Invasive Bladder Cancer & Upper Tract Urothelial Carcinoma
7.1 Muscle-Invasive Bladder Cancer (MIBC) Staging & Neoadjuvant Therapy 7.2 Radical Cystectomy & Urinary Diversion 7.3 Upper Tract Urothelial Carcinoma (UTUC)
8 Chapter 8: Renal Cell Carcinoma & Adrenal Neoplasms
8.1 Histological Subtypes, Genetics & Staging of RCC 8.2 Localized RCC: Nephron-Sparing Surgery & Radical Nephrectomy 8.3 Metastatic RCC & Targeted / Immunotherapy Regimens 8.4 Adrenal Masses & Incidentalomas
9 Chapter 9: Testicular Germ Cell Tumours & Penile Cancer
9.1 Testicular Cancer Diagnosis, Staging & Tumour Markers 9.2 Management of Seminoma (Stage I to Metastatic) 9.3 Management of Non-Seminoma (Stage I to Metastatic) 9.4 Penile Cancer: Staging, Organ-Sparing & Lymphadenectomy
10 Chapter 10: Benign Prostatic Hyperplasia & Lower Urinary Tract Symptoms
10.1 BPH Pathophysiology, Natural History & Clinical Evaluation 10.2 Medical Management of Male LUTS / BPO 10.3 Interventional & Surgical Management of BPO
11 Chapter 11: Functional Urology, Incontinence & Neuro-Urology
11.1 Urinary Incontinence in Men and Women, Fistulae & Urethral Diverticula 11.2 Overactive Bladder, Bladder Pain Syndrome & Pelvic Organ Prolapse 11.3 Neurogenic Lower Urinary Tract Dysfunction (NLUTD) 11.4 Urodynamic Studies: Indications, Technique & Interpretation
12 Chapter 12: Urolithiasis: Evaluation & Medical Management
12.1 Stone Pathophysiology & Risk Factors 12.2 Metabolic Evaluation & Dietary/Medical Stone Prevention 12.3 Acute Ureteric Colic & Medical Expulsive Therapy
13 Chapter 13: Endourology & Interventional Stone Management
13.1 Shock Wave Lithotripsy (SWL) 13.2 Ureteroscopy (URS) & Retrograde Intrarenal Surgery (RIRS) 13.3 Percutaneous Nephrolithotomy (PCNL) & Endourological Safety
14 Chapter 14: Infections, Andrology & Male Infertility
14.1 Localised & Systemic UTIs, Pyelonephritis, Urosepsis & Specific Infections 14.2 Prostatitis, Epididymo-Orchitis & Fournier Gangrene 14.3 Male Infertility: Evaluation & Surgical Management 14.4 Erectile Dysfunction, Peyronie Disease, Priapism & Gender-Affirming Surgery
15 Chapter 15: Paediatric Urology, Trauma & Renal Transplantation
15.1 Cryptorchidism, Hypospadias & PUJO 15.2 Vesicoureteral Reflux, Posterior Urethral Valves & Nocturnal Enuresis 15.3 Genitourinary Trauma: Kidney, Bladder & Urethra 15.4 Renal Failure, Dialysis Indications & Renal Transplantation
14.3 Male Infertility: Evaluation & Surgical Management
Key Takeaways Explain This Topic AI
Infertility means no pregnancy after 12 months of regular unprotected intercourse; male factors contribute in about 30–50% of affected couples. WHO 2021 lower fifth-centile values include volume 1.4 mL, concentration 16 million/mL, progressive motility 30% and normal morphology 4%. These reference values do not by themselves distinguish fertile from infertile men.
Endocrine evaluation distinguishes primary hypergonadotropic hypogonadism (elevated FSH/LH, low testosterone, reflecting intrinsic testicular failure e.g., Klinefelter syndrome) from secondary hypogonadotropic hypogonadism (low/normal FSH/LH, low testosterone, reflecting hypothalamic-pituitary failure treatable with exogenous gonadotropins hCG and recombinant FSH). In older men, confirm symptomatic hypogonadism with repeat appropriate morning testosterone testing; individualise treatment and monitor haematocrit, prostate and cardiovascular safety.
Offer karyotyping in azoospermia or sperm concentration < 5 million/mL. Perform Y-microdeletion testing at ≤ 1 million/mL and consider it below 5 million/mL. Complete AZFa or AZFb deletions preclude useful TESE; AZFc deletions permit retrieval in about 50–70%, with transmission to sons requiring genetic counseling.
Congenital Bilateral Absence of the Vas Deferens (CBAVD) is present in 1–2% of infertile men and is strongly linked to mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene; mandatory CFTR screening of both partners is required before assisted reproduction.
OA usually has normal testicular volume and FSH and may permit reconstruction or sperm retrieval. NOA reflects impaired sperm production; testicular size and FSH are clues rather than definitive tests. Treat reversible endocrine causes; micro-TESE is the preferred retrieval method for appropriately selected men with NOA pursuing ICSI.
Last updated: November 2026
Male Infertility: Evaluation & Surgical Management
Infertility affects approximately 15% of couples attempting conception globally, with a male causative factor identified in 30% to 50% of couples (either as sole factor or combined with female factors). The urological workup must systematically delineate treatable etiologies, unmask underlying systemic or genetic pathologies, and optimize outcomes for natural conception or assisted reproductive technologies (ART).
1. Semen Analysis & WHO 2021 Guidelines (6th Edition)
Semen analysis remains the cornerstone of the laboratory evaluation of the infertile male. The World Health Organization (WHO) published its 6th Edition Laboratory Manual for the Examination of Human Semen in 2021 , establishing updated lower reference limits based on the 5th centile of fertile men whose partners achieved pregnancy within 12 months.
Pre-Analytical Standardization
Abstinence Interval : Strictly 2 to 7 days of sexual abstinence prior to collection.
Collection Technique : Sample obtained by masturbation into a sterile, wide-mouthed container; delivered to the laboratory within 60 minutes while kept between 20°C and 37°C.
Confirmation : Because semen parameters exhibit profound intra-individual biological variability, a single abnormal test is never definitive; perform at least two semen analyses if the baseline result is abnormal , with repeat timing guided by clinical circumstances. +-------------------------------------------------------------------------------------------------+
- | WHO 2021 (6TH EDITION) SEMEN REFERENCE VALUES |
- | |
- | Parameter Reference Value (see note below) |
- | ---------------------------------------------------------------------------------------------- |
- | Semen Volume >= 1.4 mL |
- | Sperm Concentration >= 16 million / mL (16 x 10^6 / mL) |
- | Total Sperm Count >= 39 million per ejaculate |
- | Progressive Motility (PR) >= 30% |
- | Total Motility (PR + NP) >= 42% |
- | Vitality (Membrane-Intact Cells) >= 54% |
- | Normal Forms (Strict Kruger Criteria) >= 4.0% |
- | Semen pH >= 7.2 |
- | Leukocytes (Peroxidase-Positive) < 1.0 million / mL (1.0 x 10^6 / mL) |
- +-------------------------------------------------------------------------------------------------+
The numerical semen reference limits above describe a fertile reference population, not a diagnostic boundary for fertility. pH and leukocyte values are separate consensus thresholds, not fifth-centile reference limits.
Standardized Descriptive Nomenclature
Normozoospermia : All ejaculate parameters (number, motility, morphology) equal to or above reference limits.
Oligozoospermia : Sperm concentration < 16 x 10^6 / mL (severe oligozoospermia: < 5 x 10^6 / mL).
Asthenozoospermia : Progressive motility < 30%.
Teratozoospermia : Normal morphological forms < 4%.
Oligoasthenoteratozoospermia (OAT) Syndrome : Simultaneous impairment across all three sperm variables.
Azoospermia : Total absence of spermatozoa in the ejaculate following centrifugation (3000 x g for 15 minutes) and microscopic pellet examination.
Aspermia : Complete absence of ejaculate fluid (retrograde ejaculation or anejaculation).
Necrozoospermia : Reduced sperm vitality; in complete necrozoospermia, no viable sperm are identified. Assess vitality with eosin-nigrosin staining or the hypoosmotic swelling test.
Leukocytospermia : Presence of >= 1.0 x 10^6 / mL peroxidase-positive white blood cells, indicating inflammation, which does not by itself establish infection or a benefit from antibiotics.
2. Endocrine Evaluation & Diagnostic Algorithm
Endocrine evaluation is indicated in all men with oligozoospermia or azoospermia , in the presence of erectile or ejaculatory dysfunction, or when physical examination reveals clinical signs of hypogonadism (e.g., gynecomastia, decreased secondary sexual hair, testicular atrophy).
Core Hormonal Axis Testing
Initial Morning Panel : Fasting morning serum Total Testosterone (measured between 08:00 and 10:00 AM due to circadian rhythms) with FSH and LH .
Reflex Hormonal Testing : If testosterone is subnormal, repeat fasting morning testosterone. Use LH to classify hypogonadism; measure prolactin for suspected secondary hypogonadism, calculate free testosterone when indicated by SHBG, and request estradiol selectively. +---------------------------------------------------------------------------------------------------+
- | DIAGNOSTIC ENDOCRINE ALGORITHM IN INFERTILITY |
- | |
- | +------------------------------------------+ |
- | | Morning Testosterone, FSH and LH | |
- | +------------------------------------------+ |
- | | |
- | +------------------------------+------------------------------+ |
- | | | |
- | v v |
- | +--------------------------------+ +--------------------------------+ |
- | | HIGH FSH & LH | | LOW / NORMAL FSH & LH | |
- | | LOW TESTOSTERONE | | LOW TESTOSTERONE | |
- | +--------------------------------+ +--------------------------------+ |
- | | | |
- | v v |
- | PRIMARY HYPOGONADISM SECONDARY HYPOGONADISM |
- | (Hypergonadotropic Hypogonadism) (Hypogonadotropic Hypogonadism) |
- | --> Intrinsic testicular failure --> Hypothalamic / Pituitary failure |
- | --> Causes: Klinefelter (47,XXY), --> Causes: Kallmann syndrome, pituitary |
- | bilateral cryptorchidism, mumps adenoma / hyperprolactinemia, |
- | orchitis, prior chemo/radiotherapy anabolic steroid (AAS) abuse |
- | --> TESE / micro-TESE for ICSI --> MEDICAL THERAPY EFFECTIVE: |
- | hCG + recombinant FSH |
- | (Exogenous T is CONTRAINDICATED) |
- | |
- | *NOTE ON ISOLATED ELEVATED FSH WITH NORMAL TESTOSTERONE & LH: |
- | Suggests impaired spermatogenesis with preserved Leydig function; it does not specify histology |
- | (loss of negative feedback inhibition from Sertoli-derived Inhibin B). |
- +---------------------------------------------------------------------------------------------------+
Caution
Exogenous Testosterone is Strictly Contraindicated in Men Desiring Fertility: Administering exogenous testosterone creates high systemic circulating androgen levels that exert profound negative feedback on the hypothalamus and anterior pituitary, shutting off pulsatile GnRH, LH, and FSH release. This reduces intratesticular testosterone (normally much higher than serum levels) and may cause severe oligozoospermia or azoospermia. Recovery after withdrawal is variable and may take months; suppression is not necessarily permanent. To stimulate spermatogenesis in hypogonadotropic hypogonadism, urologists use Human Chorionic Gonadotropin (hCG) (1500–2000 IU SC 2–3 times/week as an LH analogue) followed by recombinant human FSH (rFSH) (75–150 IU SC 3 times/week).
3. Genetic Testing Indications & Findings
Genetic anomalies account for approximately 15% of cases of non-obstructive azoospermia and severe oligozoospermia. Offer karyotyping for azoospermia or sperm concentration < 5 million/mL . Perform Y-microdeletion testing at ≤ 1 million/mL and consider it below 5 million/mL ; select other tests according to the phenotype and provide genetic counseling.
1. Karyotype Analysis (Chromosomal G-Banding)
Klinefelter Syndrome (47,XXY) : The most frequent chromosomal cause of male infertility (present in 10–15% of men with non-obstructive azoospermia). Patients present with eunuchoid body habitus, tall stature, sparse facial/body hair, gynecomastia, small firm testes (< 4 mL), and hypergonadotropic hypogonadism. While naturally infertile, focal islands of active spermatogenesis persist in up to 50% of patients, yielding a 45% to 50% sperm retrieval rate on micro-TESE for ICSI.
Robertsonian & Reciprocal Translocations : Associated with recurrent pregnancy loss, embryopathy, and severe oligozoospermia.
46,XX Male Syndrome : Translocation of the SRY gene onto the X chromosome; phenotypically male with azoospermia and zero sperm retrieval potential.
2. Y-Chromosome Microdeletions (AZF Regions)
Microdeletions occur within the Azoospermia Factor (AZF) locus on the long arm of the Y chromosome (Yq11), assessed in three principal regions: AZFa , AZFb , and AZFc . +-------------------------------------------------------------------------------------------+
- | Y-CHROMOSOME MICRODELETION REGIONS (Yq11) |
- | |
- | Complete AZFa Deletion: |
- | --> Genes involved: USP9Y, DDX3Y |
- | --> Histological phenotype: Complete Sertoli-Cell-Only (SCO) syndrome |
- | --> Clinical outcome: SPERM RETRIEVAL RATE IS VIRTUALLY 0% |
- | --> TESE / micro-TESE is STRONGLY CONTRAINDICATED; counsel on donor sperm / adoption |
- | |
- | Complete AZFb Deletion: |
- | --> Genes involved: RBMY gene family |
- | --> Histological phenotype: Complete meiotic germ cell arrest |
- | --> Clinical outcome: SPERM RETRIEVAL RATE IS VIRTUALLY 0% |
- | --> TESE / micro-TESE is STRONGLY CONTRAINDICATED; counsel on donor sperm / adoption |
- | |
- | AZFc Deletion (Most Common): |
- | --> Genes involved: DAZ (Deleted in Azoospermia) gene cluster |
- | --> Phenotype: Highly variable (severe oligozoospermia to non-obstructive azoospermia) |
- | --> Clinical outcome: EXCELLENT PROGNOSIS FOR RETRIEVAL |
- | --> TESE / micro-TESE yields viable sperm in 50% to 70% of cases |
- | --> GENETIC COUNSELING MANDATORY: 100% of male offspring conceived via ICSI will INHERIT |
- | the Y-microdeletion, with implications for their reproductive health |
- +-------------------------------------------------------------------------------------------+
- 3. CFTR Gene Mutations & CBAVD
Congenital Bilateral Absence of the Vas Deferens (CBAVD) occurs in 1% to 2% of infertile men and represents approximately 10% of obstructive azoospermia.
Genetic Etiology : Caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene on chromosome 7q31. Over 80% to 90% of men with CBAVD carry identifiable CFTR mutations (most commonly compound heterozygosity: a severe cystic fibrosis mutation such as ΔF508 paired with a mild splicing variant like the 5T allele in intron 8).
Clinical Presentation : Palpably absent bilateral scrotal vasa deferentia, hypoplastic epididymides, low semen volume (< 1.0 mL), acidic semen pH (< 7.0), and absent seminal fructose (due to concomitant congenital seminal vesicle hypoplasia/agenesis).
Mandatory Policy : Genetic testing of BOTH the male patient and the female partner must be completed prior to sperm retrieval (MESA/TESE) and ICSI. Counsel from both partners’ specific variants and genotypes : affected-child risks can be 25% when both carry one pathogenic variant or 50% when the male has two and his partner one. The phenotype may be CF or a CFTR-related disorder; severe classic CF is not inevitable.
Renal Sonography Rule : If a patient presents with vasal agenesis (unilateral or bilateral) and tests negative for CFTR mutations , obtain renal ultrasound to assess associated renal anomalies, including agenesis, which arises from early embryonic disruption of the common mesonephric (Wolffian) duct.
4. Obstructive vs. Non-Obstructive Azoospermia
Differentiating obstructive from non-obstructive azoospermia is essential because obstructive forms are frequently amenable to surgical reconstruction or direct sperm aspiration, whereas non-obstructive forms need etiological assessment, treatment of reversible endocrine causes and, when appropriate, micro-TESE for ICSI.
Diagnostic Parameter Obstructive Azoospermia (OA) Non-Obstructive Azoospermia (NOA)
Primary Pathology Mechanical conduit blockage with normal spermatogenesis Impaired sperm production from testicular or hypothalamic-pituitary causes
- Testicular Volume Normal (> 15–20 mL bilaterally) Often small; normal size does not exclude NOA
- Serum FSH Level Normal (1.5–8.0 IU/L) Often elevated in primary failure; normal or low in other forms
Epididymal Examination Distended, turgid, indurated ("full") epididymides Flat, soft, non-distended, empty epididymides
Vasa Deferentia Absent in CBAVD; present in post-vasectomy or infection Intact and palpable bilaterally
Ejaculate Profile If seminal vesicle level: volume < 1.0 mL, pH < 7.0, fructose negative Normal volume (1.5–5.0 mL), normal pH (7.2–8.0), fructose positive
Diagnostic Modalities Clinical/hormonal evaluation; TRUS for suspected distal obstruction Clinical/hormonal/genetic assessment and scrotal US; no separate routine biopsy before TESE
Surgical Options Vasovasostomy, vasoepididymostomy, TURED, PESA/MESA Microdissection TESE (micro-TESE) for ICSI
- 5. Surgical Interventions in Male Infertility
- 1. Varicocelectomy
Pathophysiology : Retrograde venous pooling in the pampiniform plexus causes testicular hyperthermia, venous stasis, tissue hypoxia, elevated hydrostatic pressure, and oxidative stress with increased Sperm DNA Fragmentation Index (DFI) .
Clinical Indications (EAU Guidelines) : The principal infertility indication combines the following features:
The varicocele is clinically palpable (Grade I: palpable on Valsalva; Grade II: palpable at rest; Grade III: visibly apparent at rest).
The couple has documented infertility of >= 12 months.
The semen analysis demonstrates documented abnormal parameters.
The female partner has a good ovarian reserve and the couple can allow time for a response. (Repair of subclinical varicoceles detected solely on Doppler ultrasound is NOT recommended) .
Gold Standard Technique : Microsurgical Subinguinal Varicocelectomy utilizing an operating microscope (8–15x magnification). This technique allows precise identification and ligation of all internal and external spermatic veins while preserving the testicular artery and lymphatics . Compared to open retroperitoneal (Palomo) or inguinal (Ivanissevich) repairs, the microsurgical approach minimizes the postoperative hydrocele formation rate to < 1% (vs. 5–10%) and reduces recurrence rates to < 1–2% .
2. Microsurgical Anastomoses for Obstructive Azoospermia
Vasovasostomy (VV) : Microsurgical two-layer or modified one-layer end-to-end reconstruction for post-vasectomy reversal or iatrogenic vasal injury. Patency rates exceed 90–95%, with natural pregnancy rates around 50–70%.
Vasoepididymostomy (VE) : Consider when examination of vasal fluid from the testicular stump suggests secondary epididymal obstruction: thick, toothpaste-like fluid without sperm or sperm parts favors VE over VV. Assess both fluid character and microscopy. Performed as a microsurgical end-to-side intussusception between the vas lumen and an isolated epididymal tubule.
Transurethral Resection of Ejaculatory Ducts (TURED) : Indicated for ejaculatory duct obstruction (EDO) caused by midline prostatic utricle cysts or post-inflammatory calcifications; unroofing may restore seminal emission and sperm output in appropriately selected obstruction.
3. Testicular Sperm Extraction: Conventional vs. Micro-TESE
In non-obstructive azoospermia (NOA), spermatogenesis is typically heterogeneous and focal, with tiny isolated "islands" of active spermatogenesis interspersed among sclerotic tubules.
Microdissection TESE (micro-TESE) :
Performed through an equatorial incision of the tunica albuginea with operating microscope magnification (15–20x).
The surgeon systematically interrogates the testicular parenchyma to selectively identify and excise dilated, opaque, wider seminiferous tubules , which have a high probability of harboring active spermatogenesis, while deliberately avoiding thin, collapsed, translucent tubules.
Clinical Selection : EAU favors micro-TESE for NOA because it targets focal spermatogenesis while limiting tissue removal and vascular injury. Reported retrieval rates vary; comparative studies do not establish a universal advantage of a fixed size. Counsel about failed retrieval and postoperative testosterone decline, and follow endocrine function.
- Summary Reference Tables: Semen, Endocrine & Genetic Profiles
- Table 1: Endocrine & Genetic Diagnostic Patterns in Azoospermia
Clinical Diagnosis Serum FSH Serum LH Serum Testosterone Testicular Volume Genetic Abnormalities Surgical / Medical Strategy
Klinefelter Syndrome (47,XXY) Markedly elevated Markedly elevated Low to low-normal Small, firm (<4 mL) 47,XXY karyotype Micro-TESE (45–50% sperm retrieval rate) for ICSI
Complete AZFa or AZFb Microdeletion Markedly elevated Normal to elevated Normal to low Small (<10 mL) Complete deletion of the AZFa or AZFb region TESE strictly contraindicated (0% retrieval); donor sperm / adoption
AZFc Microdeletion Elevated to normal Normal Normal Normal to moderately small Loss of DAZ gene cluster Micro-TESE or TESE (50–70% retrieval rate); 100% transmission to sons
Kallmann Syndrome Severely low Severely low Severely low Infantile / small (<4 mL) KAL1 / ANOS1 mutation (anosmia) Pulsatile GnRH or hCG + recombinant FSH; no TESE needed
CBAVD (CFTR Mutation) Normal Normal Normal Normal (>15 mL) CFTR mutations (e.g., ΔF508, 5T) PESA / MESA / TESE + ICSI; mandatory female CFTR screening
Exogenous Anabolic Steroids Suppressed Suppressed Variable Normal to soft / small None Stop androgens; recovery often takes 6–12 months. Persistent infertility may warrant specialist hCG±FSH or a SERM.
Obstructive Azoospermia (Post-Vasectomy) Normal Normal Normal Normal (>15 mL) None Microsurgical Vasovasostomy (VV) or Vasoepididymostomy (VE)